Email updates

Keep up to date with the latest news and content from BMC Proceedings and BioMed Central.

This article is part of the supplement: Abstracts of the 16th International Charles Heidelberger Symposium on Cancer Research

Open Access Poster presentation

The effect of cisplatin in 5637 bladder cancer cell line

Rosário Pinto-Leite1, Regina Arantes-Rodrigues2*, M Luís Cardoso3, Lúcio Santos45 and Paula A Oliveira2

Author Affiliations

1 Genetics Service, Cytogenetic Laboratory, Hospital Center of Trás-os-Montes and Alto Douro, Vila Real, Portugal

2 Department of Veterinary Sciences, CECAV, University of Trás-os-Montes and Alto Douro, Vila Real, Portugal

3 Department of Biochemistry, Faculty of Pharmacy, University of Porto, Porto, Portugal

4 Department of Surgical Oncology, Portuguese Institute of Oncology, Porto, Portugal

5 Health Faculty, Fernando Pessoa University, Porto, Portugal

For all author emails, please log on.

BMC Proceedings 2010, 4(Suppl 2):P52  doi:10.1186/1753-6561-4-S2-P52


The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/1753-6561/4/S2/P52


Published:24 September 2010

© 2010 Arantes-Rodrigues et al; licensee BioMed Central Ltd.

Poster presentation

Cisplatin is an inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. It’s been an important component of standard treatment regimens for several human malignancies including bladder cancer [1]. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition [2]. We have studied the cisplatin induced apoptotic responses of one human urinary bladder cancer cell line 5637. The cytotoxic activity of cisplatin on the survival profiles of 5637 cell line was determined by MTT assay. The survival rates of 5637 cells in the presence of 1, 2, 3, 4, and 5 μg/ml cisplatin after 72h of exposure were averaged 82.6, 55.4, 18.6, 7.2 and 7.9%, respectively. Treatment with cisplatin markedly decreased the viability of 5637 cells in a dose-dependent manner and a significant correlation was found between cell proliferation and cisplatin concentration (r = 0.964; p < 0.01).

References

  1. Piulats JM, Jiménez L, García del Muro X, Villanueva A, Viñals F, Germà-Lluch JR: Molecular mechanisms behind the resistance of cisplatin in germ cell tumours.

    Clin Transl Oncol 2009, 11:780-6. PubMed Abstract | Publisher Full Text OpenURL

  2. Konstantakou EG, Voutsinas GE, Karkoulis PK, Aravantinos G, Margaritis LH, Stravopodis DJ: Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses.

    Int J Oncol 2009, 35:401-416. PubMed Abstract | Publisher Full Text OpenURL